930TiP innovaTV 207: New dosing cohort in the open label phase II study of tisotumab vedotin in solid tumors

Abstract

Tisotumab vedotin (TV) is an investigational antibody-drug conjugate directed to Tissue Factor (TF). In the phase I/II innovaTV 201 and phase II innovaTV 204 studies, TV demonstrated encouraging antitumor activity with a manageable safety profile in patients (pts) with multiple TF-expressing tumor types. The innovaTV 207 trial is a global, open label, multicenter phase II trial assessing the safety, tolerability, and activity of TV in solid tumors known to express TF. This abstract presents the addition of Part C, testing TV in squamous non-small cell lung cancer (NSCLC) and squamous cell carcinoma of the head and neck (SCCHN).